

Bando RiPREI 2022 - Graduatoria "Full project"

N.	Project code	Affiliation	Title	Total score	Subscore (C1-C3)	Requested Budget €	Granted Budget €
1	RIPREI2023_55241c7ca120	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Antiviral treatment in patients with impaired humoral immunity and persistent SARS-CoV-2 infection: a randomised open label comparative clinical trial	47,5	27,5	400000	400000
2	RIPREI2023_7c8ae10d783c	International Centre for Genetic Engineering and Biotechnology (ICGEB)	Impact of SARS-CoV-2 variants on genome integrity and their involvement in inflammation and neuropathogenesis	47	28,5	396000	396000
3	RIPREI2023_4f63c3e5c9f0	University of Padova	Gaining insight into COVID-19 neuropathogenesis: a closer look to SARS-CoV-2 infection and driven neuroinflammation in the neuron/microglia axis	45	27	395000	395000
4	RIPREI2023_2a5f45fe4fa9	Istituto Superiore di Sanità	An innovative anti-SARS-CoV-2 vaccine based on mucosal administration of extracellular vesicles incorporating the N viral antigen	44	26	310000	310000
5	RIPREI2023_0b6c6c2dcdcb	Università degli Studi di Brescia	SARS-CoV-2 variants capability to Infect and Disseminate into different cells of the cardiovascular system and mechanisms leading to viral-induced Endothelial cell dysfunction and CARDiomyocyte damage (SIDECAR)	43,5	26	395560	395560
6	RIPREI2023_ad5d6fa48de5	University of Siena	A comprehensive toolbox for timely phenotypic characterization of novel SARS-CoV-2 variants (PHENO-BOX)	42,5	25.5	400000	400000
7	RIPREI2023_2ad9f6598b09	University of Rome "La Sapienza"	Multifocal dynamic bioengineered 3D cardiac models to unveil the epigenetic remodelling of SARS-CoV-2 infection	42	26	400000	400000
8	RIPREI2023_f5b001ceb717	University of Pisa	Decoding the pathogenesis of SARS-CoV-2: Investigating host and viral biomarkers in vitro and in an animal model across multiple viral variants	41,5	26,5	386430	386430
9	RIPREI2023_ea32c821aec8	General Inspectorate of Military Health	Molecular epidemiology surveillance of respiratory infections related to SARS-CoV-2 in military communities (MODERN-MIL).	41	25	400000	400000
10	RIPREI2023_aca6d6e03bc2	Fondazione IRCCS Policlinico San Matteo, Pavia	Evolution of SARS-CoV-2 variants And Persistence of immunity in the landscape of the Epidemiology of respiratory viral infections (ESCAPE)	41	24	393100	
11	RIPREI2023_5cbf4c716e29	Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR)	Volatile Biopsy from patients with post-Covid-19 related anosmia: electronic nose and chemometric analysis to discriminate volatile organic compounds in saliva samples.	41	23	254550	
12	RIPREI2023_4b4fad88b137	University of Turin	Exploiting SARS-CoV-2-induced Citrullination as a new strategy to develop host-targeting antiviral drugs - ESCAPE	40,5	25	397000	
13	RIPREI2023_6630979df798	University of Milan	In vitro and ex vivo characterization of the hACE2 co-factor repertoires required for efficient binding and entry of SARS-CoV-2 Variants of Concern	40	25	400000	
14	RIPREI2023_2dfcee3c6cf2	University of Piemonte Orientale	The viral sensor IFI16 at the crossroads between damage and Tolerance during human Coronavirus infection (RESISTANCE)	40	24	300300	
15	RIPREI2023_4230db7ce260	Università degli Studi di Milano	Host Response to SARS-CoV-2 variants: how different Variants of Concern (VOCs) impact innate immune response, epigenetic landscape and metabolism of infected cells.	39,5	23,5	400000	
16	RIPREI2023_76dd5a425846	National Institute for Infectious Diseases "Lazzaro Spallanzani" - IRCCS	Ex vivo and in vivo multi-omics integration for deciphering the SARS-CoV-2 persistent infection	39,5	23	398750	

17	RIPREI2023_a3b0907055ea	Scientific Department, Army Medical Center, Rome	Landscape Insights For high-throughput single cell RNA-seq lymphocytes in the SARS-CoV-2 Era (LIFE)	38	23	400000	
18	RIPREI2023_919ed39c2ea2	IRCCS Sacro Cuore Don Calabria Hospital	Understanding adaptive immune response elicited after repeated infections with SARS-CoV-2 variants of concern or vaccination boosters to improve vaccination strategies on vulnerable groups.	38	21	400000	
19	RIPREI2023_11058361e7be	University of Siena	Longitudinal analysis of the memory immune response to vaccination against SARS-CoV-2 in healthy and fragile subjects	37,5	21,5	398900	
20	RIPREI2023_ab268ed1679b	Università degli Studi di Milano	Modeling the Strategies of COVID-19 Vaccination: a dynamical model to guide the COVID-19 vaccination campaign (MoStraVa Project)	36	20,5	400000	
21	RIPREI2023_215d995d3825	University of Perugia	Exploring the interplay of host and viral factors in COVID-19 reinfections: a prospective study in health care workers	36	20	394000	
22	RIPREI2023_64544e59cb30	Istituto Superiore di Sanità	STUDY OF SARS-CoV-2 VIRAL CYCLE IN 2D AND 3D CULTURE MODELS OF PERMISSIVE INFECTION	35,5	20	400000	
23	RIPREI2023_0d22618c6f7d	Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome	PERSONNEL: Persistence, Evolution and Recovery: Study of the clinical Outcomes, Nutritional Needs and Epigenetic factors of children with Long COVID	35	20,5	400000	
24	RIPREI2023_00e6589af442	University Campus Bio-Medico of Rome	Impact of emerging SARS-CoV-2 variants in infectivity and immune escape: elucidating the potential role of indels and point mutations in the spike N-terminal domain	35	20	399080	
25	RIPREI2023_c6430124f71b	University of Rome La Sapienza	Global Antiviral strategy to address coronaviruses pandemic threats	34,5	21	400000	
26	RIPREI2023_4ce743c68ecf	University of Ferrara	Proof-of-concept studies of improvement of COVID-19 vaccine potency in the elderly	33,5	18	400000	
27	RIPREI2023_619a57b5d0ee	INMI Lazzaro Spallanzani, IRCCS	Role of ORF8 protein in the severity of SARS-CoV-2 infection	32	17	300000	
28	RIPREI2023_000c63d1e7b0	Foundation Campus Bio-Medico University Hospital, Rome	Non-invasive assessment of infections by artificial taste sensory systems in patients in long-term care facilities.	31,5	19	159900	
29	RIPREI2023_6ef9874e8cda	Azienda Ospedaliera "SS Antonio e Biagio e Cesare Arrigo", Alessandria	"SurfaCE Functionalization: an antiviral approach to Prevent the contamination of emergiNg pathogEns (CELLOPHANE)"	29	17,5	343200	
30	RIPREI2023_1206b424ade6	University of Salento	Preparedness and Countermeasures Towards Hospital-acquired Respiratory Infectious Diseases (Hospital Safety - HOSAFE)	19,5	10,5	400000	